Medtronic (NYSE:MDT) Given New $102.00 Price Target at UBS Group

Medtronic (NYSE:MDT) had its price objective upped by UBS Group from $95.00 to $102.00 in a research note issued to investors on Wednesday morning,Benzinga reports. UBS Group currently has a neutral rating on the medical technology company’s stock.

MDT has been the subject of a number of other reports. Daiwa Capital Markets upped their price objective on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, September 12th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a report on Wednesday. Argus raised their price objective on Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, August 26th. Jefferies Financial Group restated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a report on Wednesday. Finally, Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $108.50.

Medtronic Stock Down 0.7%

NYSE MDT opened at $100.12 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic has a fifty-two week low of $79.29 and a fifty-two week high of $102.59. The business has a 50 day moving average price of $94.80 and a two-hundred day moving average price of $90.70. The stock has a market cap of $128.42 billion, a PE ratio of 27.58, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison purchased 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Large investors have recently bought and sold shares of the business. Faithward Advisors LLC grew its holdings in shares of Medtronic by 7.5% during the third quarter. Faithward Advisors LLC now owns 5,405 shares of the medical technology company’s stock valued at $515,000 after purchasing an additional 379 shares during the last quarter. Sunbelt Securities Inc. boosted its position in Medtronic by 14.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 3,696 shares of the medical technology company’s stock valued at $352,000 after purchasing an additional 477 shares during the period. Captrust Financial Advisors boosted its position in Medtronic by 4.3% during the 3rd quarter. Captrust Financial Advisors now owns 134,518 shares of the medical technology company’s stock valued at $12,811,000 after purchasing an additional 5,515 shares during the period. Coldstream Capital Management Inc. grew its stake in Medtronic by 24.2% during the 3rd quarter. Coldstream Capital Management Inc. now owns 65,151 shares of the medical technology company’s stock worth $6,206,000 after buying an additional 12,694 shares during the last quarter. Finally, Danske Bank A S bought a new stake in Medtronic in the third quarter valued at $71,887,000. Institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.